600436 Zhangzhou Pientzehuang Pharmaceutical
- 237.24
- +1.58+0.67%
Zhangzhou Pientzehuang Pharmaceutical News
Wanlian Securities released a research report on April 24 stating that it gave Pien Tsai (600436.SH) a purchase rating. The main reasons for the rating include: 1) cosmetics turned losses into profits in 2023, with high growth in 2024Q1; 2) the total redu
Wanlian Securities released a research report on April 24 stating that it gave Pien Tsai (600436.SH) a purchase rating. The main reasons for the rating include: 1) cosmetics turned losses into profits in 2023, with high growth in 2024Q1; 2) the total reduction in the three cost rates of 2024Q1. (Mainichi Keizai Shimbun)
Pien Tsai (600436): The annual report and quarterly report meet expectations, and the main business maintains a good operating trend
The 2023 and 1Q24 results are in line with our expectations, Pien Tsai released the 2023 Annual Report and the 2024 Quarterly Report. Revenue in 2023 was 10.058 billion yuan, +15.69% YoY; Net Profit to Mother2
Pien Tsai (600436): High-growth cosmetics with core products turned losses under pressure from high-growth gross margins after earnings
Key elements of the report On April 19, 2024, the company released its 2023 annual report and 2024 quarterly report. In 2023, the company achieved revenue of 10.058 billion yuan (+15.69%), which went back to the mother
Pien Tsai (600436): Price increases drive rapid revenue growth in liver disease medication; dividend rate increased dramatically
We forecast the 2023-26 revenue/net profit CAGR of 13%/22%, respectively. 1Q24 performance resumed high growth; mainly driven by the liver disease medication department and cosmetics business. Reiterate the purchase and add D
Pien Tsai (600436): Strengthen brand promotion and channel building to improve Pien Tsai's strategy steady implementation
In 2023, the company achieved operating income of 10.058 billion yuan (yoy +15.69%), net profit attributable to mother of 2,797 billion yuan (yoy +13.15%), net profit not attributable to mother of 2,854 billion yuan (yoy)
Pien Tsai Hsiang (600436): Cost side is under pressure, 24Q1 performance exceeds expectations
Incident: Pien Tsai released the 2023 Annual Report and 2024 Quarterly Report. In 2023, the company achieved revenue of 10.058 billion yuan (+15.69% YoY) and net profit of 2,797 billion yuan (YoY +13).
Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) defied analyst predictions to release its first-quarter results, which were ahead of market expectations. Results were good overall, with
Pien Tsai (600436): Steady growth in performance is expected to continue in the future
Guide to this report: The company released its 2023 annual report and 2024 quarterly report. 23 All sectors grew steadily throughout the year, increased marketing, and continued broadening channels to help future growth. 24Q1 performance was steady, and the market was still showing a strong sales trend.
DBS Securities released a research report on April 22 stating that it gave Pien Tsai (600436.SH) a better rating than the market. The main reasons for the rating include: 1) the company released its 2023 annual report; 2) steady growth in main products; 3
DBS Securities released a research report on April 22 stating that it gave Pien Tsai (600436.SH) a better rating than the market. The main reasons for the rating include: 1) the company released its 2023 annual report; 2) steady growth in main products; 3) strengthening market management and terminal activities. (Mainichi Keizai Shimbun)
The third generation of medicine has lost 150 billion
Growth is still ongoing
Pien Tsai (600436): Main product volume stabilized, price increased, dividend ratio raised to 50%
1Q24 revenue and non-net profit increased 21% year-on-year, 28%. The company announced 2023 revenue of 10.06 billion yuan (+15.7% yoy), and net profit of 2.80 billion yuan (+13.2% yoy).
Pien Tsai Hsiang (600436): Performance is in line with expectations, profitability is improving steadily
Key investment events: Pien Tzai released its 2023 annual report and 2024 quarterly report. In 23, it achieved revenue of 10.058 billion yuan (+15.69% year-on-year) and net profit of 2,797 billion yuan (year-on-year +13).
rare! Can a cash dividend of 1.4 billion dollars last year and 100 billion yuan of mid-term dividend plans drawn up in advance this year restore investors' “confidence”?
① Pien Tsai will distribute a cash dividend of 1.4 billion yuan, accounting for 50.04% of the company's net profit to the mother in 2023. At the same time, the company drew up a 2024 mid-term profit distribution plan to distribute 50% of the company's net profit to the mother for the corresponding period. ② Quarterly and year-on-year data improved. Revenue for the first quarter was 3.171 billion yuan, up 20.58% year on year, and gross profit margin of 47.26% increased by 5.74 pct compared to last year's Q4.
Express News | Pien Tsai: Net profit of 2023 of 2,797 billion yuan increased 13.15% year-on-year, and plans to distribute 10 to 23.20 yuan
Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) Investors Are Less Pessimistic Than Expected
When close to half the companies in China have price-to-earnings ratios (or "P/E's") below 31x, you may consider Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) as a stock to avoid entirely
Express News | Pien Tsai and others set up a life and health technology partnership with an investment of 10 million
Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Shareholders Have Earned a 17% CAGR Over the Last Five Years
Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) shareholders might be concerned after seeing the share price drop 12% in the last quarter. But that doesn't change the fact that shareholde
Express News | Jiulongjiang Group: Adding another 830,000 shares of Pien Tsai as “21 Jiulongjiang MTN002 (green)” pooled assets
Is Zhangzhou Pientzehuang Pharmaceutical., Ltd's (SHSE:600436) Latest Stock Performance A Reflection Of Its Financial Health?
Zhangzhou Pientzehuang Pharmaceutical's (SHSE:600436) stock is up by a considerable 15% over the past week. Given the company's impressive performance, we decided to study its financial indicators m
Pien Tsai (600436): Product sales are improving, and performance is growing steadily
Key points of investment are expected to achieve a net profit growth rate of no less than 25% in the first quarter of 2024. During the beginning of 2024, the company's product sales momentum improved, the market showed a strong sales trend, and successfully achieved a “good start”. The company started with the market
Analysis
Price Target
No Data
